PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Drug Metabolism And Disposition

• Publication date

  2001-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 11181501
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reprints and Subscriptions Permissions

  2003cited by this paper
• Semenogelin , the Predominant Protein in Human Semen

  2001cited by this paper
• Doxorubicin-Induced Cardiomyopathy

  2000cited by this paper
• A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

  2000cited by this paper
• Chemotherapy in advanced prostate cancer.

  1999cited by this paper
• Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.

  1998cited by this paper
• Doxorubicin-induced cardiomyopathy.

  1998cited by this paper
• Prostate-specific antigen forms complexes with human alpha 2-macroglobulin and binds to the alpha 2-macroglobulin receptor/LDL receptor-related protein.

  1998cited by this paper
• Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer.

  1997cited by this paper
• Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.

  1997cited by this paper
• Pharmacokinetic considerations of regional administration and drug targeting: Influence of site of input in target tissue and flux of binding protein

  1996cited by this paper
• Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

  1994cited by this paper
• Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.

  1993cited by this paper
• Human pharmacokinetics of N‐l‐leucyl‐doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities

  1992cited by this paper
• Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin.

  1991cited by this paper
• Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

  1989influential reference
• Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa.

  1989cited by this paper
• Clinical Pharmacokinetics of Doxorubicin

  1988cited by this paper
• A commentary: methods and assumptions in the kinetic estimation of metabolite formation.

  1983cited by this paper
• LNCaP model of human prostatic carcinoma.

  1983cited by this paper

• Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy.

  2021cites this paper
• Synthesis and evaluation of new 4-peptidamido-2-fluorobenzyl phosphoramide mustard conjugates as prodrugs activated by prostate-specific antigen

  2020cites this paper
• Synthesis and evaluation of new peptide-linked doxorubicin conjugates as prodrugs activated by prostate-specific antigen

  2020influential citation
• Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design.

  2019cites this paper
• Light-induced mechanisms for nanocarrier's cargo release.

  2019cites this paper
• Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]

  2018cites this paper
• A review of drug release mechanisms from nanocarrier systems.

  2017cites this paper
• Dexamethasone-( c 21-phosphoramide )-[ anti-egFr ] : molecular design , synthetic organic chemistry reactions , and antineoplastic cytotoxic potency against pulmonary adenocarcinoma ( a 549 )

  2016cites this paper
• Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)

  2016cites this paper
• Gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)

  2016cites this paper
• Improving the Specificity of the Prostate‐Specific Antigen Substrate Glutaryl‐Hyp‐Ala‐Ser‐Chg‐Gln as a Promoiety

  2015influential citation
• Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine

  2015cites this paper
• Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer

  2015cites this paper
• PRODRUG AND RECEPTOR MEDIATED DRUG TARGETING STRATEGIES OF PROSTATE CANCER

  2015cites this paper
• Mechanisms of drug release in nanotherapeutic delivery systems.

  2015cites this paper
• Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole

  2013cites this paper
• Proteolytic profiling with imaging agents for rational design of target-activated peptide prodrugs

  2012cites this paper
• Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

  2012cites this paper
• Peptide‐mediated targeted drug delivery

  2012cites this paper
• Synthesis of a Covalent Epirubicin-(C3-amide)-Anti-HER2/neu Immunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate

  2012cites this paper
• Protease-Activated Drug Development

  2012cites this paper
• Enzyme-mediated hydrolytic activation of prodrugs

  2011cites this paper
• Clinical management of doxorubicin-induced heart failure.

  2011cites this paper
• A new daunomycin-peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro.

  2011cites this paper
• Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma.

  2011cites this paper
• It is all about proteases: from drug delivery to in vivo imaging and photomedicine.

  2011cites this paper
• Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer

  2010cites this paper
• New daunomycin–oligoarginine conjugates: Synthesis, characterization, and effect on human leukemia and human hepatoma cells

  2009cites this paper
• Doxorubicin conjugates for selective delivery to tumors.

  2008cites this paper
• Development of Tumour-Selective and Endoprotease-Activated Anticancer Therapeutics

  2008cites this paper
• Novel peptidylaminoarylmethyl phosphoramide mustards for activation by prostate-specific antigen

  2008cites this paper
• Tumour endoproteases: the cutting edge of cancer drug delivery?

  2008cites this paper
• Towards a ligand targeted enzyme prodrug therapy: Single round panning of a β‐lactamase scaffold library on human cancer cells

  2007cites this paper
• Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.

  2007cites this paper
• Molecular-docking-guided design, synthesis, and biologic evaluation of radioiodinated quinazolinone prodrugs.

  2007cites this paper
• Targeting - Cancer — Small Molecules

  2007cites this paper
• Prodrugs of Amines

  2007cites this paper
• Selective delivery of therapeutic agents for the diagnosis and treatment of cancer

  2006cites this paper
• Engineering of human coagulation factor X variants activated by prostate-specific antigen

  2005cites this paper
• Matrix metalloproteinase–activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity

  2005cites this paper
• Targeted therapies for prostate cancer

  2005cites this paper
• Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

  2004cites this paper
• Tumor-activated Prodrugs—A New Approach to Cancer Therapy

  2004cites this paper
• Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.

  2004cites this paper
• Micelle delivery of doxorubicin increases cytotoxicity to prostate carcinoma cells

  2004cites this paper
• HPLC-MS/MS determination of a peptide conjugate prodrug of doxorubicin, and its active metabolites, leucine-doxorubicin and doxorubicin, in dog and rat plasma.

  2003cites this paper
• Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.

  2003cites this paper
• In situ moisture determination of a cytotoxic compound during process optimization.

  2003cites this paper
• Design and development of novel DNA Topoisomerase inhibitors.

  2003cites this paper
• Drug-targeting strategies for prostate cancer.

  2003cites this paper
• Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

  2003cites this paper
• A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.

  2002cites this paper
• CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.

  2002cites this paper
• The determination and use of optimized protease substrates in drug discovery and development.

  2002cites this paper
• Investigations into the chromatographic behavior of a doxorubicin-peptide conjugate.

  2002cites this paper
• Recent progress in drug delivery systems for anticancer agents

  2002cites this paper
• CPI-0004 Na , a New Extracellularly Tumor-Activated Prodrug of Doxorubicin : In Vivo Toxicity , Activity , and Tissue Distribution Confirm Tumor Cell Selectivity 1

  2002cites this paper
• Design and Synthesis of a Selective PSA Cleavable Peptide-Doxorubicin Prodrug Which Targets PSA Positive Tumor Cells

  2001cites this paper
• In vivo targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two γ-linked glutamate residues at the COOH terminus.

  2001cites this paper
• The role of pro-drug therapy in the treatment of cancer.

  2001cites this paper
• Prodrug strategies in cancer therapy.

  2001cites this paper
• The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.

  2001cites this paper
• Enzymatic Activation of Proteasome Inhibitor Prodrugs by Prostate-Specific Antigen as Targeted Therapy for Prostate Cancer

  2000cites this paper